Business Model Breakdown
How IN8bio Inc Makes Money
INAB
Market Cap
$14M
The Short Version
IN8bio is a clinical-stage biotechnology company focused on developing a novel class of cellular therapies, specifically allogeneic gamma-delta T-cells, to treat various cancers. They do not currently generate revenue from product sales. Instead, their business model involves incurring significant research and development expenses to advance their drug candidates through preclinical and clinical trials. The long-term goal is to bring these therapies to market, generating revenue through licensing agreements with larger pharmaceutical companies or by commercializing the therapies themselves if approved. Success hinges on positive clinical trial outcomes and regulatory approvals.
Where the Revenue Comes From
No current revenue streams; future potential from product sales or licensing (~100% of future revenue)
Potential grant funding (minor and intermittent)
Who buys: Currently, no direct customers for commercial products. Future customers would be patients with specific cancers (e.g., glioblastoma, leukemia), referred by oncologists and treated in hospitals or specialized clinics.
Why It Works (Competitive Advantages)
- ✔Proprietary allogeneic gamma-delta T-cell platform (INB-100, INB-200/400, INB-600)
- ✔Early clinical data suggesting survival improvements in glioblastoma vs. standard care
- ✔Potential for off-the-shelf allogeneic therapies (reducing cost/complexity vs. autologous CAR-T)
Economic Moat: Narrow (Intangible Assets/IP (proprietary cell therapy platform and related patents), Switching Costs (for physicians/hospitals once a therapy is approved and integrated into practice))
What Our Analysis Says
DVR Score as of April 16, 2026
IN8bio maintains a compelling, high-risk, high-reward profile driven by its innovative allogeneic gamma-delta T-cell therapies for high-unmet-need cancers like GBM and AML. The Total Addressable Market is substantial, and the platform promises scalability for exponential growth upon success. While scientific leadership is strong and early clinical milestones are the primary execution indicators, the core challenges persist. IN8bio remains a pre-revenue biotech, heavily reliant on binary clinical outcomes, facing significant cash burn, and an ongoing need for future dilutive capital. The auditor's going concern warning highlights this precarious financial position. No new material changes have occurred since the last analysis (2026-03-13) to warrant a score adjustment, hence the consistent score of 65/100, reflecting immense long-term disruptive potential balanced against very early-stage financial and clinical risks.